- ABOUT STERITAS
- STERITAS GTI
- CLINICAL SCIENCE
At Steritas, we address the challenges of measuring and minimizing steroid-toxicity to improve the standard of care for millions of patients around the world. We developed the Steritas GTI (Glucocorticoid Toxicity Index) to enable clinicians to track the direct impact of steroid-toxicity.
Today, the GTI provides a precise measure of the efficacy and safety of new therapies that treat inflammatory diseases and minimize the side-effects associated with glucocorticoid use.
We provide clinicians and patients with the tools to track steroid-toxicity so they can taper steroid usage and optimize treatment outcomes.
We solve the challenge of measuring and minimizing steroid-toxicity. The Steritas GTI was developed by an international group of 20 subspecialty experts and clinical investigators in: rheumatology, pulmonary medicine, nephrology, neurology, psychiatry, dermatology, ophthalmology, pharmacology, maternal-fetal medicine, and infectious disease. The instrument was developed using data-driven analysis, expert consensus, and multi-criteria decision informatics.
Ms. Stone, the CEO of Steritas, has decades of experience as a professional strategist advising leaders across a range of industries in the US.
Ms. Stone, the CEO of Steritas, is driven by the scope of the public health problem addressed by Steritas and the opportunities to scale the company’s technologies to improve the quality of care for millions of adult and pediatric patients worldwide. She envisions the deployment of Steritas technologies in clinical trials, at point of care, and with a global public health initiative.
In founding Steritas, she recognizes that the company’s core technology - the Steritas GTI - has met the moment. Conservative estimates of individuals taking long-term glucocorticoids at more than 50 million adults (1% of the world’s population). She has assembled the Steritas team to license and leverage the technology to improve health across all steroid-dependent diseases. This undertaking draws on both individual patient experience and global physician expertise to improve the lives of men, women, and children whose treatment still depends heavily on steroids. To contribute to the creation of new therapeutic strategies and treatment pathways that reduce steroid toxicity is a gratifying way to serve the public.
Martha, driven by the thrill of enterprise and love of language, is a business and brand strategist at heart. She has helped design and execute global manufacturing strategies with companies such as Hewlett-Packard and Autodesk and consulted with the leaders in a range of mid-sized companies seeking to differentiate their service offerings to grow market share.
As Communications Director of American Promise in its start-up phase, she worked to drive the adoption of the 28th Amendment to the United States Constitution, based in rare national, bi-partisan consensus that people – not big money, not large corporations, not powerful unions, and not special interests – must govern themselves.
Stone earned a degree in English from Williams College where, with a wink at the school mascot – the Purple Cow – she built and branded her first successful business: Holey Cow Mending, a thymbol of quality. A later enterprise, launched while the mother of young children, was Perpetual Cow Productions. That company created a best-selling audio CD called for crying out loud TM unlikely sounds to calm your baby. The collection of white noise to soothe fussy infants that sold online, in independent shops, and through large chain stores, was also included in a state-wide program to equip 5000 new parents with coping strategies to help prevent shaken baby syndrome. for crying out loud garnered attention from The Wall Street Journal, NPR’s Morning Edition, and a variety of parenting media channels.
From the whimsical to the great challenges in public health, Martha Stone understands the way people and business operate, and her body of work has been to create strategies that attract, build and secure community in support of good works.
Dr. Stone, a rheumatologist, is a Professor of Medicine at Harvard Medical School and the Edward A. Fox Chair in Medicine at the Massachusetts General Hospital.
Dr. Stone graduated from Harvard Medical School, completed his internal medicine training at Johns Hopkins University School of Medicine, and trained in rheumatology at the University of California-San Francisco. Before being recruited to Mass General, he co-founded and directed the Vasculitis Center at Johns Hopkins. His work focuses on vasculitis, a group of inflammatory diseases that target blood vessels, as well as on a newly-described multi-organ condition known as IgG4-related disease (IgG4-RD).
Dr. Stone led randomized, double-blind, placebo-controlled trials in both ANCA-associated vasculitis and giant cell arteritis. The results of those trials led directly to the worldwide approval of new treatments for those diseases.
In the early days of the COVID pandemic, Dr. Stone developed and led a decisive trial of an anti-cytokine therapy, the BACC Bay Trial, across 7 Boston hospitals. He has assembled a creative research group to tackle IgG4-RD, a condition largely unknown in the U.S. before his arrival at Mass General in 2008. He has hosted or co-hosted four international symposia on IgG4-RD, designed and conducted clinical trials of novel medications for this condition, and fostered collaborations with the Ragon Institute in Cambridge, Massachusetts that have led to new insights into human immunology.
Since 2015, drawing on 25 years of experience with glucocorticoid treatments for his own patients, Dr. Stone has focused on the measurement and prevention of glucocorticoid toxicity. He organized the international group of experts to create the Glucocorticoid Toxicity Index (GTI) in adults and a second collaboration among pediatricians to develop the pediatric version of the instrument, the pGTI.
Dr. Stone seeks to facilitate the transition of treatment for patients with inflammatory diseases such into an era of safe, highly-effective, steroid-sparing medications.
Dr. Paul Brunetta is a physician and clinical researcher and is currently the Head of Clinical and Translational Science at Sana Biotechnology which is advancing cell and gene therapies into the clinic.
Dr. Paul Brunetta is a physician and clinical researcher with 14 years of clinical care experience and 19 years of experience in the biotechnology industry and drug development He is a graduate of Johns Hopkins University in Baltimore and Tufts University School of Medicine in Boston. He went to UCSF at the height of the AIDS epidemic and did his internship and medical residency at UCSF. Paul was Chief Medical Resident at San Francisco General Hospital (1993-1994) and then did his Pulmonary and Critical Care Fellowship at UCSF before joining faculty focusing on lung cancer, tobacco-related lung disease, and smoking cessation. He co-founded the Fontana Tobacco Treatment Center and has dedicated significant volunteer time to support FTTC expansion within the UCSF clinical system over the years. He recently co-authored the book Learning To Quit- a comprehensive guide to smoking cessation. Paul is a co-founder of Mobile Applications for Connected Health, a private company developing a comprehensive smoking cessation platform undergoing clinical research at the University of Colorado mHealth Impact Lab in the School of Public Health.
Paul joined the biotech industry in 2002 and has supported the approval of multiple monoclonal antibody therapies and has significant experience interacting with the FDA and EMA in the drug approval process. He has designed, monitored, and implemented trials in autoimmune drug development spanning phase I-IV trials across multiple diseases in neurology, nephrology, rheumatology, immunology, pulmonary medicine, and solid organ transplantation. His clinical research work has been published in the New England Journal of Medicine and other international specialty journals. Paul directed the Genentech Clinical Research Fellowship for 12 years, mentoring fellows across multiple disease areas. Paul joined Juno Therapeutics as SVP, Head of Translational Science in CAR-T development. He’s now Head of Clinical and Translational Science at Sana Biotechnology which is advancing next-generation cell and gene therapies into the clinic.
Dr. Halvorsen is the VP of Clinical Operation at CinCor Pharma, Inc., an accomplished scientist with extensive experience in clinical research and therapeutics development.
Dr. Halvorsen has served in a leadership capacity at the Translational Medicine Group of Massachusetts General Hospital. She is an accomplished scientist and the inventor of multiple patents. She has extensive experience in clinical research and therapeutics development.
Dr. Halvorsen has successfully advanced multiple molecules from basic research to late-stage clinical investigation programs - these include small molecule drugs for diabetes, major depressive disorders, hypertension as well as biotechnology products for anemia, autoimmune diseases and vaccines.
As the CEO of Q32 Bio, Mr. Broxson brings more than 20 years of biopharma leadership experience across operations, finance, strategy, new product planning, alliance management and corporate development.
Prior to joining Q32 Bio, Mike was Chief Business and Operating Officer at Goldfinch Bio. In that role he built the G&A functions, oversaw fundraising efforts, and closed strategic transactions with Gilead and Takeda. Mike spent 16 years at Takeda Pharmaceuticals, most recently as vice president and global head of R&D business development. He also established Takeda’s externalization practice, establishing new ventures and innovative alliances to support R&D assets.
Mike began his career as a toxicologist for CH2M Jacobs, a global engineering consulting firm. He holds a B.A. in Economics and an M.S.P.H. in Toxicology from Tulane University, an M.B.A. from the University of Chicago and is a CFA® charter holder. He is a former board member of Molecular Templates, Inc. (MTEM).
Mr. Schulz has served in a number of senior positions in both the for profit and nonprofit sectors.
Mr. Schulz was a consultant with McKinsey & Company, President of Recycler Classifieds, and SVP and General Manager at Yahoo! In the nonprofit sector. He was President of the American Red Cross Los Angeles Region and Vice President of the California Community Foundation.
Paul has sat on numerous boards including Goodwill of Southern California, the California Community Foundation, Roadtrip Nation, Big Brothers Big Sisters of Los Angeles, the Center For Nonprofit Management, UCLA Center for Global Health, and the Martha's Vineyard Nonprofit Collaborative.
He received his BA from Claremont McKenna College and his MA from Oriel College Oxford where he was a Rhodes Scholar.
Professor Yoshiya Tanaka, M.D., Ph.D. is Professor and Chairman of the First Department of Internal Medicine, School of Medicine and Dean of Graduate School of Medical Science, University of Occupational and Environmental Health, Japan.
Professor Tanaka has authored and reviewed nearly 600 publications. His scientific focus lies on pathological analysis and development of novel treatments for systemic autoimmune diseases, rheumatic diseases, and osteoporosis. He is the president of the Japanese Association of Clinical Immunology and past president of Japanese Society of Bone and Mineral Research (JSBMR).
He is a director and board member of the Asia Pacific League of Associations for Rheumatology (APLAR), Japanese Society of Internal Medicine, Japanese College of Rheumatology (JCR), Japanese Society of Inflammation and Regeneration.
He is also editor-in-chief of Modern Rheumatology Case Reports, an associate editor of Rheumatology, Cytokine, Arthritis Care and Research, Arthritis Research & Therapy, Inflammation Research, International Journal of Rheumatic Diseases, an editorial board member of Annals of Rheumatic Diseases, RMD Open, Modern Rheumatology, and Inflammation Research. He has received numerous awards from the Japanese Society of Inflammation, JSBMR, JCR, and EULAR.
Dr. Goyal specializes in the diagnosis, management, and electrophysiological testing of neuromuscular disorders (including SFEMG), with expertise in immune-mediated disorders (myositis, myasthenia gravis, CIDP, and vasculitis) and ALS.
Dr. Goyal is a Clinical Associate Professor in Neurology and Neurological Sciences at Stanford and specializes in the diagnosis, management, and electrophysiological testing of neuromuscular disorder (including SFEMG), with expertise in immune-mediated disorders (myositis, myasthenia gravis, CIDP, and vasculitis) and ALS. Her research interests include the monitoring and management of short and long-term toxicity of immunosuppressive agents. She also provides botulinum toxin for the treatment of sialorrhea in ALS patients.
Dr. Neelam Goyal completed her medical school education at SUNY Downstate in Brooklyn, NY. She then finished her neurology residency including her chief year followed by a fellowship year in neurophysiology with a focus on neuromuscular disorders and EMG nerve conduction studies at Stanford University Medical Hospital.
After graduation, she joined the faculty of Stanford University School of Medicine in 2012 as a Clinical Assistant Professor of Neurology and Neurological Sciences in the division of Neuromuscular Medicine. She took on the position of co-Director of the Muscular Dystrophy Association/ALS Clinic in 2016. In 2020, she was promoted to Clinical Associate Professor. She serves on multiple committees within Stanford, including the Clinical Assistant Professor Appointment and Promotions Committee and Health Information Management Committee, as well as multiple committees within the American Association of Neuromuscular and Neurodiagnostic Medicine (AANEM).
Dr. Christopher-Stine is a Professor of Medicine and Neurology and the Director of the Johns Hopkins Myositis Center. She currently serves as the Deputy Director of Telemedicine in the Division of Rheumatology and seeks to utilize this outreach effort to extend both clinical and research care in the future.
Dr. Christopher-Stine graduated Cum Laude with a B.A. in chemistry from Franklin and Marshall College where she was elected to the Phi Beta Kappa Honor Society. She was elected to the Alpha Omega Alpha medical honor society at Hahnemann University School of Medicine, where she received her MD degree. She attained her Master of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Her internship and residency training in Internal Medicine were completed at MCP Hahnemann University, where she also served as Chief Resident. She pursued rheumatology fellowship training and joined the faculty of the Division of Rheumatology at Johns Hopkins University in 2003 and became a full professor in 2022.
She serves as a board member of the Institutional Review Board at the Johns Hopkins University and she is one of 24 core faculty members to teach in the Johns Hopkins Medical School Colleges Advisory Program, which provides clinical skills instruction in the first year of medical school and continued career advising throughout all four years of medical school.
As a clinician-scientist, she co-developed and is the Principal Investigator for the Myositis Database, currently numbering well over 2000 patients recruited worldwide. She has a strong interest in patient-reported outcomes and has been the co-chair of an international effort through the OMERACT organization to develop a novel patient-reported outcome measure.
Dr. Marc A. Judson is the Chief of Pulmonary and Critical Care in Albany, New York and is affiliated with multiple hospitals including Albany Medical Center and Albany Stratton Veterans Affairs Medical Center.
Dr. Judson is a Professor of Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at Albany Medical College. He is internationally known in the field of sarcoidosis, a disease of unknown cause that affects the lung and other organs of the body.
He is currently the President of the Americas Association of Sarcoidosis and other Granulomatous Disorders, the American sarcoidosis medical society. He is currently ranked as the number one expert in the world concerning sarcoidosis and pulmonary sarcoidosis by expertscape.com.
He has published more than 100 articles concerning the disease and runs one of the largest sarcoidosis clinics in the Northeast. Dr. Judson’s other areas of expertise include interstitial lung diseases and fungal diseases of the lung. He received his medical degree from Vanderbilt University School of Medicine and has been in practice for more than 20 years.
Dr. Michael Levy is an Associate Professor in Neurology who was recently recruited to lead the research unit in the new Division of Neuroimmunology at the Massachusetts General Hospital.
Dr. Levy’s mission at Massachusett General Hospital is to build a combined clinical and research neuroimmunology program to develop therapies for patients with autoimmune diseases of the central nervous system. Clinically, Dr. Levy specializes in taking care of children and adults with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease and acute disseminated encephalomyelitis and is the principal investigator on several clinical studies and drug trials for these conditions.
Dr. Levy previously held faculty positions at Johns Hopkins University as well as being the Director of the Neuromyelitis Optica Clinic.
In addition to editing Neuroimmunology Reports, Dr. Levy is a co-chief editor at Multiple Sclerosis and Related Disorders as well as a member of the editorial boards at the Journal of Neurological Sciences and Scientific Reports.
Dr. Wen Zhang is a Professor in the Rheumatology Department at Peking Union Medical College Hospital (PUMCH), Beijing, China and has been working as a physician for 29 years.
Dr. Zhang has focused on IgG4-related disease since 2011. Her expertise encompasses IgG4-RD, Sjogren’s syndrome, Systemic lupus erythematosus, systemic vasculitis, antiphospholipid syndrome, SAPHO syndrome. She also participated in international consensus guidelines on the management of IgG4 related-disease, and the 2019 ACR/EULAR classification criteria for IgG4-RD.
Dr. Zhang received her Ph.D. degree in Rheumatology, Department of Rheumatology, Peking Union Medical College, Beijing, China, and her M.D. degree in Medicine, West China Medical University, China
Professor Gerald B. Appel, MD, is Co-Director of Clinical Nephrology at New York-Presbyterian Hospital/Columbia University Medical Center in New York, New York, and is a tenured Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons.
Dr. Appel is Director of the Glomerular Kidney Disease Center at Columbia and his career has been devoted to the care and welfare of patients with diseases of the kidney.
Dr. Appel has authored and co-authored over 300 peer-reviewed articles and book chapters. He has received numerous awards including the Albert Douglas Award of the Medical Society of NY State for excellence in clinical teaching, The Lester Honig Award of the NY-NJ Kidney Foundation, the Distinguished Service Award of the Nephcure Foundation, and twice the Teacher of the Year Award by Columbia University's medical school classes. In 2012 he delivered the Dornfeld Lecture at George Washington University and the Chandos Lecture at the UK Society of Nephrology. He was awarded The Donald Seldin Award by the National Kidney Foundation in 2012.
Dr. Appel has served as an officer and President of The NY Society of Nephrology, he has served on the Medical Advisory Board and as the Chairman of the Research Committee of the National Kidney Foundation (NKF) of NY-NJ and The Kidney and Urology Foundation of America, and as Chair of the Council of Glomerulonephritis of the NKF of the United States. Professor Appel has been listed in New York Magazine as one of the “Best Doctors in New York” annually between 1992 and 2013, and is listed in “Best Doctors in America,” He has served on the editorial board of a number of journals including roles as an Associate Editor of Clinical JASN and he is currently on the editorial board of Up-To-Date. He has been the director of a number of educational courses including The Columbia University Internal Medicine Course in NYC, Renal Biopsy in Medical Diseases of the Kidney in NYC, and for many years had directed the annual course in The Treatment of Glomerular Diseases at the American Society of Nephrology meetings (1998-2010).
He earned his undergraduate BA from Cornell University graduating with distinction and is a member of Phi Beta Kappa. He received his medical degree from Albert Einstein College of Medicine, NY in 1972 where he was elected to the medical honor society Alpha Omega Alpha. He completed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center, then completed fellowships in nephrology at both Columbia-Presbyterian Medical Center and at Yale-New Haven Medical Center in New Haven, Connecticut.
Dr. Joshua R. Korzenik, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and assistant professor at Harvard Medical School. He is a longstanding member of the medical advisory committee for the New England chapter of Crohn’s and Colitis Foundation of America.
Dr. Joshua R. Korzenik, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and assistant professor at Harvard Medical School.
Dr. Korzenik has been involved in IBD research and care of patients for almost 25 years, and has two main research focuses: translational research in IBD; and investigating environmental influences in IBD - with a focus on their common nexus of the intestinal microbiome. Dr. Korzenik is the author of almost 60 peer-reviewed articles and research papers.
As a young doctor, Dr. Korzenik was drawn to IBD because it was a poorly understood, chronic condition. While he has seen advances in the understanding of genetic and other factors affecting IBD, the role of diet and other environmental influences are still poorly understood in his view.
Dr. Korzenik earned his bachelor’s degree from Harvard College in 1980 and his medical degree from Albert Einstein College of Medicine in the Bronx, New York, in 1987. He was a resident at Harvard-affiliated Beth Israel Deaconess Hospital in Boston from 1987 to 1990 and fellow in gastroenterology and clinical epidemiology at Yale University School of Medicine Hospital from 1991 to 1994. He is a longstanding member of the medical advisory committee for the New England chapter of Crohn’s and Colitis Foundation of America.